ACADIA Pharmaceuticals Inc. (ACAD)
Stock Price:
$39.25 USD
-0.99 (-2.45%)
Updated Aug 12, 2020 1:09 PM EDT - Market open
Key Info
| Market Cap |
6.19B |
| Revenue (ttm) |
393.08M |
| Net Income (ttm) |
-225.18M |
| Shares Out |
157.68M |
| EPS (ttm) |
-1.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$39.25 |
| Previous Close |
$40.23 |
| Change ($) |
-0.99 |
| Change (%) |
-2.45% |
| Day's Open |
40.62 |
| Day's Range |
39.11 - 40.95 |
| Day's Volume |
1,490,566 |
| 52-Week Range |
23.77 - 58.72 |
More Stats
| Market Cap |
6.19B |
| Enterprise Value |
5.53B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
157.68M |
| Float |
115.43M |
| EPS (basic) |
-1.47 |
| EPS (diluted) |
-1.47 |
| FCF / Share |
-0.89 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.82M |
| Short Ratio |
5.15 |
| Short % of Float |
11.00% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.74 |
| PB Ratio |
10.26 |
| Revenue |
393.08M |
| Operating Income |
-236.84M |
| Net Income |
-225.18M |
| Free Cash Flow |
-138.60M |
| Net Cash |
658.65M |
| Net Cash / Share |
4.18 |
| Gross Margin |
20.12% |
| Operating Margin |
-60.25% |
| Profit Margin |
-57.30% |
| FCF Margin |
-35.26% |
| ROA |
-24.10% |
| ROE |
-42.81% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (16)
| Buy |
15 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$59.12*
(50.64% upside)
Low
42.0
Current: $39.25
High
71.0
Target: 59.12
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 339 | 224 | 125 | 17.33 | 0.06 | 0.12 | 1.15 | 4.91 | 2.07 | 42.14 |
| Revenue Growth | 51.5% | 79.19% | 620.68% | 28311.48% | -49.17% | -89.52% | -76.67% | 137.4% | -95.09% | - |
| Gross Profit | 328 | 211 | 116 | 14.26 | 0.06 | 0.12 | 1.15 | 4.91 | 2.07 | 42.14 |
| Operating Income | -247 | -247 | -292 | -273 | -165 | -93.23 | -38.30 | -20.89 | -22.85 | 15.09 |
| Net Income | -235 | -245 | -289 | -271 | -164 | -92.48 | -37.95 | -20.85 | -22.77 | 15.14 |
| Shares Outstanding | 147 | 127 | 123 | 116 | 101 | 97.25 | 85.72 | 55.12 | 52.18 | 38.59 |
| Earnings Per Share | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 |
| Operating Cash Flow | -151 | -167 | -218 | -208 | -122 | -66.43 | -31.77 | -21.63 | -19.90 | -10.70 |
| Capital Expenditures | -1.13 | -2.10 | -0.81 | -1.51 | -2.14 | -0.18 | -0.61 | 0.25 | - | 0.13 |
| Free Cash Flow | -152 | -170 | -219 | -210 | -124 | -66.61 | -32.38 | -21.38 | -19.90 | -10.58 |
| Cash & Equivalents | 702 | 478 | 344 | 531 | 216 | 322 | 186 | 108 | 31.05 | 37.09 |
| Total Debt | 6.36 | - | - | - | - | - | - | - | 0.03 | 0.08 |
| Net Cash / Debt | 696 | 478 | 344 | 531 | 216 | 322 | 186 | 108 | 31.02 | 37.01 |
| Assets | 783 | 540 | 385 | 561 | 222 | 325 | 189 | 109 | 32.11 | 38.39 |
| Liabilities | 84.05 | 61.12 | 49.22 | 42.74 | 22.13 | 15.97 | 6.99 | 5.95 | 8.75 | 8.71 |
| Book Value | 699 | 479 | 335 | 518 | 200 | 309 | 182 | 84.98 | 23.36 | 29.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ACADIA Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
570 |
| CEO |
Stephen R. Davis |
Stock Information
| Ticker Symbol |
ACAD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ACAD |
| IPO Date |
May 27, 2004 |
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.